Prospective Phase II Study of Preoperative Radiotherapy and Oral Capecitabine followed by Total Mesorectal Exicision (TME) in Locally Advanced Rectal Cancer.

Slides:

Advertisements

Similar presentations

Neoadjuvant therapy for Rectal cancer

Advertisements

I I. B.- T R E A T M E N T P L A N: DOCETAXEL 75 mg/m2 40 mg/m2 THORACIC RT (66 Gys: 180 cGy/d) CISPLATIN 40 mg/m2 Days E V A L U A.

Multimodality Therapy of Rectal Cancer Robert D. Madoff, MD University of Minnesota.

Rectal Cancer: Advanced Technologies Chris Willett, M.D. Department of Radiation Oncology Duke University Medical Center Durham, NC.

A phase I dose escalating study of intensity modulated radiation therapy (IMRT) for the treatment of glioblastoma multiforme (GBM) ( #1008) V. Stieber.

Rectal Cancer: A Complete Clinical Response…Now what?

Abstract Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer A. Cercek, K.

Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.

PREOPERATIVE HYPOFRACTIONED RADIOTHERAPY IN LOCALIZED EXTREMITY/TRUNK WALL SOFT TISSUE SARCOMAS EARLY STUDY RESULTS Hanna Kosela; Milena Kolodziejczyk;

Management of Locally Advanced Rectal Cancer Joint Hospital Surgical Grand Round Pamela Youde Nethersole Eastern Hospital Dr. YH Ling 19 May 2007.

Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemo-radiotherapy for locally advanced rectal cancer: Long term results.

C. ENG 1, G. J. CHANG 2, P. DAS 3, M. RODRIGUEZ-BIGAS 2, J. M. SKIBBER 2, W. QIAO 4, G. L. ROSNER 4, L. T. UKEGBU 1, R. A. WOLFF 1, C.H. CRANE 3 DEPARTMENT.

A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.

Patterns of Care in Medical Oncology Neoadjuvant and Adjuvant Treatment of Rectal Cancer.

Pneumonectomy for Locally Advanced Lung Cancer after Neoadjuvant Concurrent Chemo-radiation Therapy K. Okabe, H. Tao, T. Tanaka, T. Hayashi, K. Yoshiyama,

Intergroup trial CALGB 80101

Chemoradiotherapy for Rectal cancer Dr. A. Sun Myint Lead Clinician GI Tumour Group Clatterbridge Centre for Oncology Association of Coloproctology of.

Is Radiation Consistently Necessary for Mid-High Rectal Cancers? Assigned Viewpoint: No Great Debates Symposium New York City, NY Deb Schrag MD Dana Farber.

1 Phase II trial of sequential gemcitabine and carboplatin followed by paclitaxel as first-line treatment of advanced urothelial carcinoma Presented by.

Sphincter preserving surgery after preoperative treatment for ultra-low rectal carcinoma. A French multicenter prospective trial: GRECCAR 1 P Rouanet,

Phase II Trial of Continuous Course Re- irradiation Concurrent with Weekly Cisplatinum and Cetuximab for Recurrent Squamous Cell Carcinoma of The Head.

Pancreatic Cancer Ali Shamseddine MD Proessor of Medicine AUBMC

Definitive chemo-radiotherapy for esophageal cancer; failure pattern and salvage treatments Ryuta Koike, Y. Nishimura, K. Nakamatsu, S. Kanamori, M. Okubo,

INT Translational research in head and neck cancer: preoperative chemotherapy in oral cavity cancer based on disease molecular profiling. Paolo Bossi MSO.

What is the Preferable Treatment Option for T1/T2 Low Rectal Cancer? Christopher H. Crane, M.D. Program Director, GI Section Department of Radiation Oncology.

No Effect on Tumor Response with Weekly Oxaliplatin Added to Standard Preoperative 5-FU/RT in locally Advanced Rectal Cancer Ali Shamsedddine, MD Professor.

PHASE I TRIAL OF CONCURRENT CHEMORADIOTHERAPY USING DOXIFLURIDINE AND PACLITAXEL IN ADVANCED BREAST CANCER H.Hirowatari 1, K. Karasawa 1,2,

CR07 results and informed patient consent David Sebag-Montefiore Leeds Cancer Centre.

Transanal Endoscopic Operation Indication – Technique – Results M. Sailer Department of Surgery Bethesda Hospital – Hamburg, Germany.

H. Emama M.D.. (Radiation Therapy) By: H. Emami Assistant professor of Radiation Oncology, Isfahan University of Medical Sciences, Isfahan, IRAN.

Preoperative chemoradiotherapy and postoperative chemotherapy with 5-FU and oxaliplatin versus 5-FU alone in locally advanced rectal cancer: First results.

Anal Cancer - Case 1  62 years old woman with 6 months history of anal pain  Clinically T 3 squamous cell carcinoma growing anteriorly  Which staging.

Rectal Cancer: French Prodige Study: Best of ASCO, Beirut, July 2009 Prof Eric Van Cutsem, MD, PhD Digestive Oncology Leuven, Belgium.

Preoperative fluorouracil (FU)-based chemoradiation +/- weekly oxaliplatin in locally advanced rectal cancer. Pathologic response analysis of the STAR.

Taiwan 2000 Comparative evaluation in tolerance of neoadjuvant versus adjuvant docetaxel based chemotherapy in resectable gastric cancer in a randomized.

Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from.

Accuracy of EUS in diagnosis of rectal cancer KKUH experience

THE OUTBACK TRIAL A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared.

Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl,

MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.

Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemo-radiotherapy for locally advanced rectal cancer: Long term results of a randomized phase.

Bortezomib (VELCADE), Rituximab, Cyclophosphamide, Dexamethasone (VRCD) combination therapy in front-line low-grade non-Hodgkin lymphoma (LG-NHL) is active.

CapOx given concurrently to neoadjuvant RT improved pathologic response and tumor regression 2 in phase II trials. Synergy of cetuximab and RT has been.

Jens Jakob 1 ; Anna Simeonova 2 ; Bernd Kasper 3 ; Ulrich Ronellenfitsch 1 ; Frederik Wenz 2 ; Peter Hohenberger 1 1 Department of Surgery, 2 Department.

. Background Paclitaxel and Irinotecan in Platinum Refractory or Resistant Small Cell Lung Cancer: a Galician Lung Cancer.

Michael Stahl on behalf of the German Oesophageal Cancer Study Group PreOperative Chemotherapy or Radiochemotherapy in Esophago- gastric Adenocarcinoma.

Preliminary Results of the MRC CR07 / NCIC CO16 Randomized Trial Short course pre-op vs selective post-op chemo-RT for rectal cancer Local Recurrence after.

Dr Mark Saunders Christie Hospital and Paterson Institute of Cancer Research “ Rectal cancer radiotherapy – why do we give it and how do we do it?”

Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.

Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.

Role of Radiation Therapy in Brain metastasis Bongkot Supawongwattana, M.D. Division of Therapeutic Radiology and Oncology, Faculty of Medicine, Chiang.

Multidisciplinary treatment of rectal cancer. Medical oncology Carlo Aschele E.O. Ospedali Galliera – Genova - Italy Carlo Aschele E.O. Ospedali Galliera.

Single-agent nab-Paclitaxel Given Weekly (3/4) as First-line Therapy for Metastatic Breast Cancer (An International Oncology Network Study, #I )

Addition of Chemotherapy to Preoperative Radiotherapy Improves Outcomes in Rectal Cancer Slideset on: Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal.

PHASE II TRIAL OF HYPOFRACTIONATED BREAST IRRADIATION WITH VMAT-SIB TECHNIQUE: TOXICITY AND EARLY CLINICAL ASSESSMENT IN 270 PATIENTS F. De Rose¹, F. Alongi¹,

ADJUVANT CAPECITABINE AND OXALIPLATIN FOR GASTRIC CANCER AFTER D2 GASTRECTOMY (CLASSIC): A PHASE 3 OPEN-LABEL,RANDOMISED CONTROLLED TRIAL Yung-Jue Bang*,

Taipei Veterans General Hospital Practices Guidelines Oncology Rectal Cancer Version

Short-term outcome of neo-adjuvant chemotherapy

in locally advanced rectal carcinoma (LARC): The phase II TRUST trial

Results of Definitive Radiotherapy in Anal Canal Carcinoma

นายแพทย์ธราธร ตุงคะสมิต นายแพทย์ชำนาญการพิเศษ โรงพยาบาลมะเร็งอุดรธานี

盧建璋, 陳鴻華, 李克釗, 胡萬祥, 張家駱, 蔡鎧隆, 林岳民, 鄭功全, 吳昆霖

Neoadjuvant therapy of rectal cancer – how can we make it better?

What is the most appropriate therapy for a 50 year old patient with T3N+ rectal cancer and isolated resectable liver metastases? Systemic chemotherapy->chemoradiation->surgery.

Evaluate the results of concomitance chemoradiotherapy postoperative treatment for rectal cancer in stage II-III At K Hospital from 2012 to 2016 Speaker:

PRESENTATOR: MD VƯƠNG NHẤT PHƯƠNG. HO CHI MINH CITY ONCOLOGY HOSPITAL

Effect of Neoadjuvant Concurrent Chemoradiotherapy on Locally Advanced Middle and Low Rectal Cancer— A Propensity Score Matching Study 官泰全,林春吉,楊純豪,姜正愷,林宏鑫,藍苑慈,

Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemoradiotherapy for locally advanced rectal cancer: safety results of a randomized phase III.

RTOG 9704: A Phase III Study of Adjuvant Pre and Post Chemoradiation 5-FU vs. Gemcitabine for Resected Pancreatic Adenocarcinoma A U.S. GI INTERGROUP.

Presentation transcript:

Prospective Phase II Study of Preoperative Radiotherapy and Oral Capecitabine followed by Total Mesorectal Exicision (TME) in Locally Advanced Rectal Cancer JH Kim M.D. 1, J Park M.D. 1, EK Choi M.D. 1, SD Ahn M.D. 1 S Lee M.D. 1, SS Shin M.D. 1, JC Kim M.D. 2, CS You M.D. 2 HC Kim M.D. 2, TW Kim M.D. 3, HM Chang M.D. 3, MH Ryu M.D. 3 Department of 1 Radiation Oncology, 2 Surgery, 3 Internal medicine Asan Medical Center, College of Medicine, University of Ulsan

OBJECTIVES To evaluate the tumor response, sphincter preservation effect and acute toxicity of preoperative chemoradiation therapy using oral capecitabine for locally advanced rectal cancer

MATERIALS AND METHODS Prospective phase II trials January 2002 – February 2004 Locally advanced rectal adenocarcinoma Preoperative radiotherapy and oral capecitabine

INCLUSION CRITERIA Histologically proven rectal adenocarcinoma Locally advanced rectal cancer in clinical evaluation Tumor distal border located within 10 cm from AV. ECOG performance score 0 – 2 Adequate hematologic, renal, hepatic function Approved informed consent

PRETREATMENT EVALUATION History taking and physical examination CBC, serum chemistry, CEA Sigmoidoscopy or colonoscopy with biopsy Endorectal (or transrectal) ultrasound Abdominal pelvic CT Chest X ray Chest CT (CEA > 20ng/ml), bone scan (CEA > 40ng/ml)

TREATMENT SCHEME ( Chemotherapy ) Preoperative - 1,650 mg/m 2 /day, whole period of radiotherapy - Given orally, divided into two doses Postoperative - 2,500 mg/m 2 /day (D1-14, every 3 weeks) x 4

6, 15 MV photon Multiple field technique (3 or 4 portals) Whole pelvis 46 Gy / 23 Fr. with tumor boost 4 Gy 5 days / week TREATMENT SCHEME ( Radiotherapy )

TREATMENT SCHEME #1#2#3#4 CT RT SURGERYSURGERY Capecitabine 1,650 mg/m 2 /day 50 Gy / 25 Fr. Capecitabine 2,500 mg/m 2 /day

PATIENT CHARACTERISTICS ( I ) Characteristics No. (%) Patient number 95 Age (years) Median 55 Range 31 – 75 Sex M 68 (72) F 27 (28) Performance status 1 95 (100) (ECOG) Histologic Diff. W/D 21 (22) M/D 58 (61) P/D 5 (5) Other 11 (12)

PATIENT CHARACTERISTICS ( II ) Characteristics No. (%) Distance from AV (cm) Median 5 Range Mobility Mobile 15 (16) Tethered 44 (46) Fixed 31 (33) Unpalpable 5 (5)

Clinical stage * No. (%) T3N013(14) T3N1-256(59) T4N0 4(4) T4N1-222(23) Total 95(100) PATIENT CHARACTERISTICS ( III ) * Based on EUS and CT evaluation

Modality No. (%) Planned radiation dose Complete 92(97) Incomplete 3(3) Planned chemotherapy dose Complete 92(97) Incomplete 3(3) RESULTS : Compliance RESULTS

Extent of resection No. (%) Microscopically complete92(98) Microscopically incomplete 2(2) Macroscopically incomplete 1(1) Total* (%)94(100) RESULTS : Extent of resection RESULTS * One patient did not have surgery due to multiple metastasis.

RESULTS : Pathologic response I pT T stage pCRpT1pT2pT3pT4 cT3 (n=68) cT4 (n=26) Total* (%) 12 (13) 3 (3) 24 (26) 52 (55) 3 (3) RESULTS - T down-stage: 54/94 (57%) * One patient did not have surgery due to multiple metastasis.

pN N stage pN0 pN1-2 cN0 (n=17) 11 6 cN1-2 (n=77) 5324 Total* (%) 64 (68) 30 (32) - N down-stage: 53/77 (69%) RESULTS : Pathologic response II RESULTS * One patient did not have surgery due to multiple metastasis.

T level down-stage N level down-stage Complete response Overall down-stage 69 % (53/77) 76 % (71/94) 100 % 12 % (11/94) 57 % (54/94) 50 % RESULTS RESULTS : Pathologic response III

RESULTS : Sphincter preservation RESULTS Tumor distance from anal verge (cm) Op. 0 – 56 – 10 LAR 40 * 37 APR 14 3 Total * Sphincter preservation rate (AV ≤ 5 cm) : 74% (40/54) Elongation of distal tumor margin: 0.8 ± 1.3 cm (mean ± SD; cm) Safe sphincter preservation rate: 37% (20/54)

RESULTS : Acute toxicity (Hematologic) RESULTS Grade* Leucopenia41 (43%)19 (20%) 1 (1%)- Neutropenia27 (28%) 5 (5%) 1 (1%)- Anemia46 (48%) 7 (7%) -- Thrombocytopenia 1 (1%) - -- Toxicity *NCI CTC V2.0

RESULTS : Acute toxicity (Nonhematologic) RESULTS Grade* Proctitis33 (35%) 7 (7%) -- Diarrhea 3 (3%) 3 (3%)3 (3%)- Hand-foot syndrome 9 (10%) 3 (3%) -- Radiation dermatitis 1 (1%)14 (15%) -- Stomatitis 5 (5%) - -- Nause17 (18%) 2 (2%) - - Vomiting 3 (3%) 1 (1%) - - Weight loss 1 (1%) Toxicity *NCI CTC V2.0

PERIOPERATIVE COMPLICATIONS Complication * No. (%) Mechanical ileus1 (1) Delayed wound healing2 (2) Wound infection1 (1) Wound dehiscence2 (2) Perianal abscess1 (1) Anastomotic leak1 (1) Total8 (9) * Within 60 days from surgery

Results of Preoperative Chemoradiation with Capecitabine AuthorsNo. No.StagingRT doseDrug*T stageN stageOverall stage Cinical pCR † T4workup down down downresponse Kim 45 4EUS/CT50.4 Gy XL 63% 90% 84% - 31% (2002) / 28 Fr. (24/38) (26/29) (32/38)(12/38) Kocakova34 NR ‡ EUS50.4 Gy X 100% 100% 100% - 21% (2003) / 28 Fr. (7/34) Shi Gy X % - 18% (2004) / 30 Fr. (20/28) (5/28) Dunst58 50% Gy X 74% % 4% (2004) / 31 Fr. (37/50) (30/49) (2/50) Wong18 0EUS/CT50.4 Gy X 28% 86% 50% - 17% (2004) /MRI / 28 Fr. (5/18) (6/7) (9/18) (3/18) De Paoli53 13% Gy X % 58% 24% (2004) / 28 Fr. (29/51) (31/53) (12/51) Dupois51 1EUS/CT 45 Gy X 59% % (2004) /MRI / 25 Fr. Current 95 26EUS/CT 50 Gy X 57% 69% 76% - 12% trial / 25 Fr. (54/94) (53/77) (71/94) -(11/94) *X=capecitabine, L=leucovorin, † pCR=pathologic complete remission rate, ‡ Not reported

CONCLUSIONS 1.Preoperative chemoradiation with oral capecitabine and conventionally fractionated radiotherapy achieved encouraging rates of tumor downstaging, enabling more sphincter preservation, and reducing multivisceral resection with low acute toxicity in this trial. 2.This combined modality was safe, effective, and convenient treatment for locally advanced rectal cancer